Overview
Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).
Indication
No indication information available.
Associated Conditions
- Breast Cancer
- Melanoma
- Oral Cancer
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2021/07/01 | Phase 2 | Completed | Navidea Biopharmaceuticals | ||
2020/12/10 | Early Phase 1 | Terminated | John O. Prior | ||
2020/08/12 | Phase 2 | Terminated | |||
2020/07/27 | Phase 4 | Withdrawn | |||
2020/02/07 | Phase 4 | UNKNOWN | Anna Cruceta | ||
2019/09/20 | Phase 1 | Terminated | |||
2019/09/04 | Phase 2 | Terminated | Navidea Biopharmaceuticals | ||
2019/05/06 | Phase 2 | Completed | Navidea Biopharmaceuticals | ||
2018/01/19 | Phase 2 | Completed | Eben Rosenthal | ||
2017/08/07 | Phase 1 | Withdrawn | Navidea Biopharmaceuticals |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
Withdrawn | 11/19/2014 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.